Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Eastman Chemical (EMN) director transaction: On 10/07/2025, a director acquired 487 phantom stock units under the Directors' Deferred Compensation Plan, recorded at $0 as an automatic deferral of a portion of annual retainer fees. Following this, the director beneficially owned 1,267 phantom stock units. These units track the value of common stock and are payable only in cash after the director’s service ends. The total includes 19 units credited since April 7, 2025 from dividend-equivalent reinvestments.
Brett D. Begemann, a director of Eastman Chemical Co. (EMN), received a total of 1,827 phantom stock units on 10/07/2025 under the Directors' Deferred Compensation Plan. These units represent cash‑payable credits tied to the issuer's common stock and were recorded as voluntary and automatic deferrals of director retainer fees; 1,340 units were a voluntary deferral and 487 units an automatic deferral. The filing shows 55,811 common‑share equivalents beneficially owned after the transaction, which includes 1,178 units from reinvested dividend equivalents credited since 05/01/2025. The units have no exercise price and are payable only in cash after termination of director service.
Insider transaction summary: A director of Eastman Chemical Co. (EMN) recorded a non‑cash acquisition of 487 phantom stock units on 10/07/2025. The units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of annual retainer fees that would otherwise have been paid in cash. Phantom units track the market value of one share and are payable in cash after the director's service ends. Following the transaction the reporting person beneficially owns 13,391 common‑stock‑equivalent units, which includes 268 units credited since 05/01/2025 for reinvested dividend equivalents.
Director Humberto P. Alfonso reported acquisitions of phantom stock units under the company's Directors' Deferred Compensation Plan that convert to cash after he leaves the board. On 10/07/2025 he voluntarily deferred 1,178 units (valued at $62.35 each in the filing) and had an automatic deferral of 487 units, for a total of 1,665 newly credited phantom units.
Following these entries, he beneficially owns 53,576 shares (or share-equivalents) in a direct form. The filing notes 1,130 additional units credited since 5/01/2025 from hypothetical reinvestment of dividend equivalents. The units are payable only in cash under the plan.
Eastman Chemical Company disclosed an executive succession and related compensation changes after its Senior Vice President - Chief Technology and Sustainability Officer, Chris M. Killian, notified the company he will retire effective December 31, 2025 for family and health reasons. To lead the transition, Stephen G. Crawford will return as Executive Vice President - Technology Projects on November 3, 2025, then move to Executive Vice President - Chief Technology Officer and Chief Sustainability Officer on January 1, 2026.
Mr. Crawford’s package includes a $705,000 base salary, an annual bonus opportunity at 85% of base (prorated for 2025), an $800,000 sign-on payment to replace forfeited equity and satisfy prior severance obligations, and a restricted stock unit award with a grant-date fair value of $2,200,000 to be granted on or about January 2, 2026. He will also participate in standard executive benefit programs.
Michelle H. Caveness, Senior Vice President and Chief Manufacturing Officer of Eastman Chemical Co. (EMN), reported changes in her beneficial ownership on transactions dated 10/01/2025. She received a payout of 6,715 restricted stock units (RSUs) upon completion of a three-year vesting period, recorded as an acquisition. Simultaneously, 1,636 shares were withheld to satisfy tax liabilities at a reported price of $61.96 per share. After these transactions the filing shows 6,246 shares beneficially owned. The Form 4 was signed by power of attorney on 10/02/2025.
Adrian James Holt, Senior Vice President and Chief Human Resources Officer of Eastman Chemical Company (EMN), reported an acquisition on 08/28/2025 of 2,200 Phantom Stock Units under the company Executive Deferred Compensation Plan. Each phantom unit has a value equal to one share of common stock and is payable only in cash, subject to certain acceleration and early withdrawal provisions. The report shows a deemed price of $68.18 per share and lists 2,200 units beneficially owned following the transaction, held directly. The Form 4 was signed by Mark D. Austin by power of attorney on 08/29/2025.
Insider purchases and deferred-compensation award reported for Eastman Chemical (EMN)
Brian Travis Smith, an executive (EVP, AFP, Mfg., WWEC & HSE) reported acquiring 1,750 shares of Eastman common stock at a price of $68.34 per share, bringing his direct beneficial ownership to 16,732 shares. Separately, he was credited with 2,200 phantom stock units under the company Executive Deferred Compensation Plan; those units have a value tied to the company common stock at $68.18 per share and are payable in cash, with the report showing 2,208 underlying shares equivalent following the award. The phantom units are subject to plan terms including limited acceleration and withdrawal provisions and are payable after termination of employment. The filing reflects routine insider equity purchases and a deferred-compensation award that links pay to the issuer stock value.
James J. O'Brien, a director of Eastman Chemical Company (EMN), reported a purchase of company shares. On 08/27/2025 he acquired 1,450 shares of Common Stock at a price of $68.811 per share. After the transaction he beneficially owned 6,828 shares directly and had an indirect interest in 1,022 shares held in a revocable trust. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025.
Insider purchase reported: Eastman Chemical Company director Kim Ann Mink purchased 1,450 shares of EMN common stock on 08/27/2025 at a price of $69.3799 per share. After the transaction she beneficially owned 2,840 shares. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025. No derivative transactions or other comments are reported in the filing.